Nintedanib bremst Krankheitsprogression über ILD-Subgruppen hinweg
- 26 October 2021
- journal article
- Published by Springer Science and Business Media LLC in Pneumo News
- Vol. 13 (5), 16-19
- https://doi.org/10.1007/s15033-021-2759-z
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trialEuropean Respiratory Journal, 2020
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialThe Lancet Respiratory Medicine, 2020
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesThe New England Journal of Medicine, 2019
- Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative studyThe Lancet Respiratory Medicine, 2019
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseThe New England Journal of Medicine, 2019
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2014
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisThe New England Journal of Medicine, 2012